Key result
Virus-like particles serve as promising nanocarriers for the intracellular delivery of biomolecules and drugs by combining the key advantages of viral and non-viral vectors.
Why the study?
Great progress has been achieved but multiple challenges remain for the broad application of virus-like particles as delivery vectors for intracellular delivery of biomolecules and drugs.
This review highlights the potential and challenges of using virus-like particles as nanocarriers for the intracellular delivery of various biomolecules and therapeutic compounds.
VLPs remain investigational for biomolecule delivery; leaves open clinical translation in cardiovascular settings pending prospective trials.
Virus-like particles (VLPs) are nanostructures assemble from viral proteins. Besides widely used for vaccine development, VLPs have also been explored as nanocarriers for cargo delivery as they combine the key advantages of viral and non-viral vectors. While it protects cargo molecules from degradation, the VLP has good cell penetrating property to mediate cargo passing the cell membrane and released into cells, making the VLP an ideal tool for intracellular delivery of biomolecules and drugs. Great progresses have been achieved and multiple challenges are still on the way for broad applications of VLP as delivery vectors. Here we summarize current advances and applications in VLP as a delivery vector. Progresses on delivery of different types of biomolecules as well as drugs by VLPs are introduced, and the strategies for cargo packaging are highlighted which is one of the key steps for VLP mediated intracellular delivery. Production and applications of VLPs are also briefly reviewed, with a discussion on future challenges in this rapidly developing field.
No takes yet. Share an insight, caveat, or question.
He et al. (2022) reported a review. Virus-like particles (VLPs) was evaluated. Virus-like particles serve as promising nanocarriers for the intracellular delivery of biomolecules and drugs by combining the key advantages of viral and non-viral vectors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: